{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}],"title":"Baseline To Low"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"title":"Baseline To Normal or No Change"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"title":"Baseline To High"}],"title":"Pulse Rate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"Baseline To Low"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}],"title":"Baseline To Normal or No Change"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"title":"Baseline To High"}],"title":"Temperature"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The abnormal vital sign ranges were: For pulse rate (low \\<60 beats per minute \\[bpm\\] and high \\>100 bpm); For body temperature (\\<=35 degrees Celsius or \\>=38 degrees Celsius). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case change from baseline was presented as Baseline to low, Baseline to Normal or No change and Baseline to High.","groups":[{"description":"Participants were administered 2.5 mg/kg of belantamab mafodotin in combination with 200 mg of pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal , or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation"},{"description":"Participants were administered with 3.4 mg/kg of belantamab mafodotin in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG001","title":"Main Study Phase- Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 31 months","title":"Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature","type":"PRIMARY","unitOfMeasure":"Participants"}